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Abstract
Gene therapy represents an attractive strategy for the non-invasive treatment of prostate cancer, where current clinical
interventions show limited efficacy. Here, we evaluate the use of the insect virus, baculovirus (BV), as a novel vector for
human prostate cancer gene therapy. Since prostate tumours represent a heterogeneous environment, a therapeutic
approach that achieves long-term regression must be capable of targeting multiple transformed cell populations.
Furthermore, discrimination in the targeting of malignant compared to non-malignant cells would have value in minimising
side effects. We employed a number of prostate cancer models to analyse the potential for BV to achieve these goals. In
vitro, both traditional prostate cell lines as well as primary epithelial or stromal cells derived from patient prostate biopsies,
in two- or three-dimensional cultures, were used. We also evaluated BV in vivo in murine prostate cancer xenograft models.
BV was capable of preferentially transducing invasive malignant prostate cancer cell lines compared to early stage cancers
and non-malignant samples, a restriction that was not a function of nuclear import. Of more clinical relevance, primary
patient-derived prostate cancer cells were also efficiently transduced by BV, with robust rates observed in epithelial cells of
basal phenotype, which expressed BV-encoded transgenes faster than epithelial cells of a more differentiated, luminal
phenotype. Maximum transduction capacity was observed in stromal cells. BV was able to penetrate through three-
dimensional structures, including in vitro spheroids and in vivo orthotopic xenografts. BV vectors containing a
nitroreductase transgene in a gene-directed enzyme pro-drug therapy approach were capable of efficiently killing
malignant prostate targets following administration of the pro-drug, CB1954. Thus, BV is capable of transducing a large
proportion of prostate cell types within a heterogeneous 3-D prostate tumour, can facilitate cell death using a pro-drug
approach, and shows promise as a vector for the treatment of prostate cancer.
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Introduction
In the United Kingdom, over 40,000 new cases of prostate
cancer are diagnosed every year and 11,000 patients die as a direct
result of this disease (Source: Office for National Statistics). The
human prostate gland is a heterogeneous environment, primarily
composed of epithelial and stromal cell types. The epithelial
compartment consists of a bilayer of cells: a continuous basal layer
of undifferentiated cells that are in contact with the basement
membrane, overlaid with differentiated secretory luminal cells [1].
The basal epithelial layer represents the most proliferative
compartment [2]. While the bulk of most prostate tumours
comprises cells of epithelial origin [3], multiple cell types have the
capacity to contribute towards malignancy, and must be eradi-
cated in order to achieve an effective clinical outcome.
Typically, the stage of prostate disease and the responsiveness of
the tumour to androgens are two key factors that direct treatment
strategies. While localised prostate tumours can be surgically
resected via radical prostatectomy, this is often accompanied by
undesirable side effects. An alternative approach, androgen
ablation therapy, removes the supply of androgens that many
prostate tumours rely on for growth and survival; however, the
recurrence of more aggressive castration-resistant prostate cancer
(CRPC) is a common outcome. Since CRPC is ultimately resistant
to radiotherapy and chemotherapy, novel strategies are essential to
provide improved outcomes for prostate cancer patients. Gene
therapy is one potential solution, and would ideally be positioned
to target both primary and secondary prostate tumours following
systemic administration.
While many different vectors have been evaluated for safety and
efficacy in gene therapy trials [4], the use of non-human, non-
pathogenic viruses, such as the baculovirus, Autographa californica
Multiple NucleoPolyHedrovirus (AcMNPV), is a relatively under-
studied area. BV is a double-stranded DNA virus that naturally
infects insect hosts, and although BV can efficiently transduce
mammalian cells, productive replication is not possible due to the
requirement for insect-specific cellular machinery [5,6]. As a gene
therapy vector, BV has several inherent advantages. The bulk of
the human population has no previous exposure to BV and is thus
immunologically naive. The BV capsid is capable of expanding to
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accommodate large transgene inserts, and the natural tropism of
baculovirus is easily modified. BV is able to transduce both
actively-dividing and quiescent mammalian cells, a feature that has
particular relevance in the treatment of prostate cancer, a slow-
growing tumour [7]. The presence of baculovirus, even at a high
multiplicity of infection (MOI), is not toxic and does not affect cell
growth and differentiation potential [8,9]. Finally, extensive long-
term safety studies, undertaken in the 1960’s when baculovirus
emerged as an important prospect as a biological insecticide, have
proven baculovirus harmless to man [10].
The ability of BV to deliver functionally sustainable transgene
expression in mammalian cells was first demonstrated in 1995
[11]. Since then, AcMNPV has proven capable of transducing a
wide range of mammalian cell types, including human primary
neurons [12], liver [11], mesenchymal stem cells [13] and
embryonic stem cells [9]. While the earliest attempts to achieve
BV-mediated gene transfer in vivo failed due to vector inactivation
by serum components, such as complement [14], efficient
baculovirus transduction can be achieved in the presence of
chemical- or protein-based complement inhibitors, either as co-
inocula [15,16,17] or incorporations into the BV envelope protein
[17,18,19]. BV has been successfully used as a preclinical gene
therapy vector in vivo [12,20,21,22,23], and in the context of
cancer has successfully treated murine gastric xenografts [24].
Here, we evaluate BV as a gene therapy vector for the treatment
of human prostate cancer. We describe the use of BV to
preferentially transduce and deliver both reporter and cell-lethal
genes to malignant prostate samples of cell line and patient origin,
in addition to three-dimensional cultures and in vivo murine
tumours, with high efficiency.
Materials and Methods
Insect Cell Line Maintenance
Sf21 and Sf9 (Invitrogen) cell lines (isolated from the ovarian
tissue of the fall army worm, Spodoptera frugiperda) were maintained
in spinner hanging stir bar flasks at 27uC in Grace’s medium
supplemented with 10% foetal calf serum (PAA Laboratories) and
0.1% (v/v) PluronicH F-68 (Invitrogen). Monolayer cultures were
maintained in the absence of Pluronic.
Human Prostate Cell Line Maintenance
LNCaP (androgen-sensitive, well-differentiated prostate cancer
cells derived from a lymph node metastasis) and PC-3 (androgen-
independent, poorly-differentiated prostate cancer cells derived
from a bone metastasis) were purchased from the American Type
Culture Collection (ATCC, USA). PC346C (androgen-sensitive,
well-differentiated prostate cancer cells derived from a primary
prostate tumour) were established in the Erasmus Medical Centre,
The Netherlands [25]. P4E6 (epithelial cells derived from a well-
differentiated primary prostate tumour immortalised by transfec-
tion with HPV E6), PNT1A and PNT2C2 (non-malignant
prostate cells from different patients, respectively, immortalised
by transfection with SV40) were established in our laboratory
[26,27]. All cells were handled under good laboratory practice
conditions in defined passage windows, were monthly certified free
of mycoplasma and were genotyped (using the ATCC-approved
Powerplex 1.2 system, Promega) to ensure authenticity. Cells were
routinely passaged under previously described conditions [28].
Primary Cell Culture
Patient prostate tissue was taken with informed and written
consent and approval from the York Research Ethics Committee
from patients undergoing transurethral resection of the prostate,
cystectomy or radical prostatectomy. Epithelial cells were isolated
as described previously [29] and selected for a2b1
hi expression
using rapid adherence to type I Collagen-coated plates (BD
Biosciences). Cells were co-cultured on Collagen I plasticware with
irradiated STO murine feeder cells until growth was well
established, in KSFM supplemented with 5 ng/ml EGF, 50 mg/
ml bovine pituitary extract and 2 mM L-Glutamine (KSFMsup).
To induce differentiation, cells were cultured in a 50:50 (v/v)
mixture of DMEM and Ham’s F12, supplemented with 10% FCS,
10 nM DHT and 2 mM L-Glutamine (DH10) for 4–6 days.
Isolated stromal cells were propagated in T25 flasks in RPMI
supplemented with 10% FCS and 2 mM L-Glutamine.
Baculovirus Preparation
Recombinant baculovirus vectors were constructed using the
BacVector 1000 kit (Novagen), according to the manufacturer’s
instructions, with the custom-made pBAC64:CMV-EGFPCAT,
pBAC64:CMV-EGFP or pBAC64:CMV-NTR-EGFP transfer
plasmids. These plasmids have the backbone of pBAC4X-1
(Novagen) with insertions of the polh promoter and gp64 gene
coding sequences from pBACsurf-1 (Novagen) and the cytomeg-
alovirus (CMV) immediate early promoter driving transcription of
EGFP, an EGFPCAT fusion protein (BD Biosciences Clontech) or
mNitroreductase(NTR)-IRES-EGFP expression cassettes. Recom-
binant viruses were subjected to three rounds of plaque
purification and high titre stocks were grown by infecting Sf21
insect cells at MOI= 0.1 plaque forming units (PFU) per cell and
harvesting virus supernatant after 5 days. Virus-containing cell
supernatant was concentrated by ultracentrifugation at 24,000
RPM for 90 minutes at 4uC using a Beckman SW28 rotor and
further purified by ultracentrifugation through a sucrose gradient
at 24,000 RPM in a Beckman SW41 rotor. Virus particles were
washed and resuspended in PBS (approximately 1/500 starting
volume) and titrated using plaque assay on Sf9 cells. The
particle:PFU ratio was generally within the range of 100–300
[30,31,32]. For transduction of prostate cells, virus was diluted in
serum-free medium appropriate for each cell type, unless
otherwise stated.
Confocal Microscopy Analysis of Monolayers and Bilayers
For both monolayer and bilayer confocal experiments, cells
were seeded onto 8-well chamber slides with a coverslip base (Lab-
Tek) at an initial density of 2–56104 cells per well (pre-coated with
0.1 mg/ml poly-L-lysine for LNCaP cells). To generate a bilayer,
medium was changed every 2 days until a dual layer of epithelial
growth was achieved. BV-[CMV-EGFPCAT] or BV-[CMV-
EGFP] particles were added at 500 PFU/cell for a specified
length of time after which cells were washed to remove unbound
virus and fixed immediately in 4% (w/v) paraformaldehyde. Cells
were permeabilised in 0.5% (v/v) Triton-X 100 (Sigma) or 70%
EtOH, then blocked in 10% serum. The BV capsid protein, vp39,
was detected using a primary monoclonal antibody (P10C6),
courtesy of Dr. L.E. Volkman, University of California, Berkeley,
USA [33] and a goat anti-mouse Alexa Fluor 568 secondary
antibody (Invitrogen). In bilayer experiments, antibody dilutions
were prepared in 0.1% (w/v) Fraction V BSA (Sigma) to aid
penetration in basal layers, while in monolayer experiments,
antibody dilutions were prepared in PBS. For analysis of primary
cell differentiation, HMWCK (Dako) antibody was added with the
subsequent application of a secondary goat anti-mouse Alexa 568
antibody (Invitrogen). A second primary antibody (CK18-FITC
(Sigma)) was then applied. Vectashield containing DAPI (Vector
Lab) was added before visualising cells under fluorescence using a
Zeiss LSM 510 meta confocal microscope.
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Flow Cytometry
Cells were plated at a density of 0.2–16105 per well of a 48-well
plate and incubated at 37uC overnight. Cells were washed once in
PBS before addition of virus diluted in serum-free medium
appropriate for each cell type. After the desired length of time,
virus was aspirated, cells washed once in serum-free medium and
overlaid in serum-containing growth medium. Cells were detached
using Trypsin:EDTA and resuspended in 0.02% (w/v) EDTA,
with a minimum of 10,000 singlet events counted using a CyAnTM
ADP flow cytometer.
PC346C Spheroid Transduction
Spontaneously formed spheroids were harvested from the
surface of a T25 flask containing PC346C cells and incubated
for 10 minutes at 37uC in complete culture medium containing
BV-[CMV-EGFP] at a concentration of 8.66109 PFU/ml. The
spheroids were diluted in 2.5 ml of medium and re-plated into a
T12.5 flask. Fluorescent images were captured using a Nikon
Eclipse TE300 microscope at three days post-infection.
Orthotopic Xenografts
Tumours were established by injection of 16106 PC346C cells
orthotopically into the dorsolateral prostate of athymic nude mice
(NMRI nu/nu, Taconic M&B A/S, Ry, Denmark) as described
previously [34], in compliance with ethical procedures and under
approval from the Erasmus Experimental Animal Center ethics
committee. Tumour growth was monitored by transrectal
ultrasonography using an adapted intravascular ultrasound system
[35]. At tumour sizes between 80 and 120 mg, two doses (36107
or 16108 pfu) of BV-[CMV-EGFP] were administered intratu-
mourally under anaesthesia. Animals were sacrificed 3 days later,
tumours were harvested, fixed for 2 h in 2% (w/v) paraformal-
dehyde in PBS, sliced on a Vibratome (Campden Instruments,
Loughborough, UK) into 70 mm thick sections and mounted on
glass slides in Vectashield (Vector Lab). EGFP expression was
visualised by confocal microscopy (Carl Zeiss, Benelux).
Evaluation of Cell Viability by MTS Assay
Cells were plated at a density of 16104 cells per well in a 96 well
plate and allowed to attach overnight. BV-[CMV-NTR-EGFP]
was added to triplicate wells at MOI= 500 for 4 hours, washed
and incubated for a further 20 hours before addition of CB1954
(20 mM for all primary samples and cell lines except for PC-3, for
which 40 mM was used). After a further 48 h for cell lines or 30 h
for primary cells, cell viability was measured using the CellTiter
96H Aqueous Assay Reagent (Promega) according to the
manufacturer’s instructions and plates read using a BMG Labtech
POLARstar OPTIMA plate reader. The proportion of dead cells
was calculated by comparing to viable cells in an untransduced
well. A duplicate set of wells were used for flow cytometry as
described above to determine the frequency of positively
transduced cells.
Results
BV Transduction is Most Efficient in Malignant Prostate
Cell Lines Compared to Non-malignant Controls
In order to determine the capacity of BV to differentially
transduce malignant vs. non-malignant prostate targets, we
evaluated the susceptibility of a panel of established human
prostate cell lines to BV transduction. Cells were incubated with a
recombinant BV vector modified to carry an EGFPCAT
transgene (BV-[CMV-EGFPCAT]) using a fixed MOI of 500
and an incubation time of 48 h. Malignant cell lines with high
metastatic potential, including LNCaP, PC3 and PC346C, were
highly transduced (,80% EGFP-positive cells), while non-
malignant cell lines PNT1A and PNT2C2 were least transduced
(up to 10% EGFP-positive cells) (Figure 1A). P4E6, a cell line
derived from an initiated but early stage tumour, was in the
intermediate range, with approximately 20% EGFP-positive cells
(Figure 1A). Thus, the frequency of cells positively transduced by
BV correlated with malignancy and metastatic potential.
To investigate the optimal transduction conditions for highly
susceptible (LNCaP, PC-3) versus less susceptible (PNT1A and
PNT2C2) prostate cell lines, we analysed both the MOI required
to achieve transduction saturation and the kinetics of transduction
at this MOI. Cells were incubated for 1 h in the presence of
increasing doses of BV-[CMV-EGFPCAT], and the proportion of
EGFP-positive cells was analysed after 24 h. The MOI required to
achieve the maximum frequency of transduced cells was 500 PFU
per cell for LNCaP, PC3 and PNT1A, and 1000 PFU per cell for
PNT2C2 (data not shown). Using these saturating MOIs, the
kinetics of transduction were investigated over time. Malignant
prostate cell lines (LNCaP and PC-3) demonstrated rapid and
efficient uptake of BV-[CMV-EGFPCAT], requiring only short
incubation times (,45 or ,90 min, respectively) to reach 50% of
the levels recorded at 48 h (Figure 1B). Conversely, non-malignant
prostate cell lines (PNT1A and PNT2C2) required extended
incubation times (,10 h or ,8 h, respectively) to achieve 50% of
the levels at 48 h (Figure 1B).
One interpretation of these differences in transduction is that
nuclear import of the BV capsid is defective in some cell types
(reviewed by [36]). To evaluate this hypothesis in our prostate cell
line models, the subcellular localisation of BV capsids was
investigated using confocal microscopy at 8 h post-transduction
in the highly susceptible malignant LNCaP and PC-3 cell lines and
the less susceptible non-malignant PNT1A cell line. BV capsids
were observed in the nucleus of all three cell types (Figure 1C), and
visual analysis of multiple fields of view did not reveal any
differences in the levels of nuclear capsid localisation. However,
PC-3 cells had a higher level of surface-bound BV, whereas
PNT1A cells had a higher level of BV in the cytoplasm (Figure 1C).
Cells of Basal (Undifferentiated) Phenotype Are
Transduced More Readily than Luminal (Differentiated)
Cells in Primary Prostate Epithelial Cultures
In order to extend our evaluation of BV into a more biologically
relevant situation, we employed primary patient biopsy-derived
prostate epithelial cell cultures. Since the bulk of human prostate
tumours comprises cells of epithelial origin, with both undifferen-
tiated (basal) and well-differentiated (luminal) phenotypes present,
we determined whether BV was capable of targeting both
epithelial cell populations at different stages of differentiation.
Primary prostate epithelial cells derived from three patient tumour
biopsies (Gleason scores 6, 7 and 8/9) were cultured under two
different conditions: in KSFMsup medium to maintain cells in a
basal state, or in DH10 medium to induce differentiation, based
on work by [37]. Changes in differentiation status under these
distinct culture conditions were confirmed by immunofluorescent
analysis of classical differentiation markers (basal markers:
cytokeratins (CK) 1, 5, 10 and 14; luminal marker: CK18), based
on work by [38] (Supplementary Figure 1). On a per-patient basis,
cells cultured in KSFMsup or DH10 were incubated with BV-
[CMV-EGFPCAT] for increasing lengths of time and analysed by
flow cytometry at 48 h. Epithelial differentiation reduced trans-
duction frequencies overall when the cells were incubated with
virus for less than 10 h: for example, in cells derived from a
A Baculovirus Vector for Prostate Cancer Therapy
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Figure 1. BV transduction of prostate cell lines. (A) Percentage of EGFP-positive cells following transduction of a panel of high grade malignant
(red), low grade malignant (black) or non-malignant (blue) prostate cell lines with BV-[CMV-EGFPCAT] at MOI = 500 for 48 h. Error bars depict2/+ one
standard deviation. (B) Relative expression levels of EGFP following transduction with BV-[CMV-EGFPCAT] at a saturating MOI (500 for LNCaP, PC3 and
PNT1A, 1000 for PNT2C2). The percentage of EGFP-positive cells was normalised to the levels achieved following 48 h incubation in the presence of
virus for each cell type (set to 1). Malignant cell lines: PC3 (m), LNCaP (&); Non-Malignant Cell Lines: PNT2C2 (¤), PNT1A (.). Error bars depict 2/+
A Baculovirus Vector for Prostate Cancer Therapy
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Gleason 6 tumour, the maximum level of infection achieved in
basal (KSFMsup) cells at 4 h (45.3363.55%) was considerably
higher than the peak of infection in luminal (DH10) cells
(21.6961.78%) at 8 h (Figure 2A). Over longer periods of BV
incubation, the difference in transduction levels between
KSFMsup- and DH10-cultured cells became less pronounced,
but remained lower in differentiated (DH10) cell populations
(Figure 2A).
In order to further investigate the rapid transduction of basal
epithelial cells with BV, we employed an in vitro cell bilayer model,
which mimicks the cellular structure of the prostate gland. The
bilayer comprised a confluent layer of basal epithelial cells (CK1/
5/10/14+) overlaid with an imperfect upper layer of cells with a
more differentiated, luminal phenotype (CK18+) [28,38]. Primary
malignant prostate epithelial cells derived from a Gleason score 7
tumour were allowed to form a bilayer, then incubated with BV-
[CMV-EGFPCAT] for 1 h or 16 h and visualised using confocal
microscopy. After incubation with BV for 1 h, virus capsids were
visualised in the basal layer in a punctate staining pattern, but
were not observed in the luminal layer (Figure 2B). Following a
longer period of incubation (16 h), virus capsids were detected in
both basal and luminal layers: however, notable areas in the
luminal layer remained devoid of virus capsids (Figure 2B).
BV can Rapidly and Efficiently Transduce Primary Prostate
Stromal Cells
Epithelial and stromal populations represent the two major
cellular components of prostate tumours. While epithelial cells
typically comprise the bulk of the malignant cell population,
stromal cells have been implicated in a reciprocal feedback loop
that supports the growth and maintenance of tumour cells [39,40].
This suggests that a successful prostate cancer therapy should
include targeted eradication of the malignancy-associated stromal
compartment. We therefore investigated the ability of BV to
transduce cells of stromal origin. Stromal cells derived from
malignant or non-malignant primary prostate biopsies were
incubated with BV-[CMV-EGFPCAT] for 1, 16 or 24 hours
and analysed by flow cytometry. After 1 h, approximately 30% of
cells were transduced by BV, while after 16 h incubation, every
stromal cell was positively transduced by BV (Figure 2C). No
difference was observed in the frequency of positively-transduced
stromal cells based on malignancy; however, on a per-cell basis,
stromal cells derived from malignant prostate biopsy samples
exhibited a greater mean fluorescence intensity than those derived
from benign biopsy samples at early timepoints (Figure 2C).
Stromal cells were therefore highly susceptible to BV transduction.
BV can Successfully Transduce 3-D Prostate Spheroids
and Orthotopic Xenografts
It has been suggested that an effective gene therapy vector must
be capable of penetrating through several cell layers in order to
achieve a clinically relevant response in the treatment of solid
tumours. To characterise the ability of BV to migrate through cell
layers, we employed both in vitro and in vivo three-dimensional
cultures. For in vitro modelling, hollow spheroids of malignant
PC346C prostate cells, which comprised a ‘shell’ of 2–3 cell layers
and spontaneously detached from monolayers during routine
culture, were incubated with BV-[CMV-EGFP]. At 72 h post-
incubation, a highly efficient pattern of cell transduction was
observed, with penetration of BV through all cell layers
(Figure 3A).
For in vivo modelling, murine prostate cancer xenograft models,
generated through orthotopic injection of the PC346C cell line
into the dorsolateral prostate of athymic nude mice, were injected
intratumourally with BV-[CMV-EGFP] at two different concen-
trations (36107 or 16108 pfu). At 72 h, tumours were resected and
analysed by fluorescence microscopy. BV was observed to
successfully penetrate into the tumour, and migrate away from
the initial site of injection. This was particularly evident following
administration of the higher dose of virus (Figure 3B). Thus, even
in three-dimensional cultures, BV was capable of achieving a high
level of cell transduction.
Malignant Prostate Cells can be Efficiently Killed Using BV
Vectors in a Nitroreductase-based GDEPT Approach
In order to test the ability of BV to achieve a cell-lethal
outcome, we employed a gene-directed enzyme pro-drug therapy
(GDEPT) approach focussed on bacterial nitroreductase (NTR),
which converts the pro-drug CB1954 (5-(aziridin-1-yl)-2,4-dini-
trobenzamide) into a potent DNA cross-linking agent [41].
Therefore, we constructed a BV bearing an expression cassette
where the strong mammalian CMV promoter drove expression of
mNTR-IRES-EGFP (BV-[CMV-NTR-EGFP]). A panel of ma-
lignant and non-malignant prostate cell lines were transduced with
BV-[CMV-NTR-EGFP], and cell viability was evaluated follow-
ing administration of the pro-drug, CB1954. The proportion of
non-viable cells, as measured by MTS assay after 48 h, was
significantly higher in malignant samples with high metastatic
potential (PC346C, PC3 and LNCaP) compared to non-malignant
samples (PNT1A and PNT2C2) (P,0.001) (Figure 4A). Early-
stage malignant samples (P4E6) fell into the intermediate range of
viability. Furthermore, cell viability following pro-drug adminis-
tration was directly related to the rate of BV transduction
(Figure 4A). This analysis was extended into primary patient-
derived epithelial cell cultures. Three malignant and two non-
malignant samples were transduced with BV-[CMV-NTR-EGFP]
and treated with CB1954. At 30 h post-pro-drug administration,
cell death in these cultures ranged from 10% to 50%, irrespective
of disease status (Figure 4B).
Discussion
Multiple models of disease have demonstrated that baculovirus
has great potential as a novel vector for gene therapy. Here, we
have explored its utility for the treatment of human prostate
cancer. BV was capable of efficiently transducing a range of
prostate cells derived from multiple sources, including in vitro and
in vivo models. BV demonstrated differential transduction of
malignant compared to non-malignant prostate cells, an observa-
tion that appeared independent of growth rate, since the cell lines
in question exhibited similar proliferative capacities (doubling
times: PNT2C2 (39 h), LNCaP (34 h) PC-3 (30–34 h) and PNT1a
(30 h) [26,42,43]). Although a primary mammalian cellular
receptor for BV attachment remains unidentified, we speculate
that malignancy-associated upregulation of heparan sulphate-
modified proteoglycans (HSPGs) on the tumour cell surface
[44,45], which are known to be involved in BV binding [16,46],
plays a role in this outcome. The kinetics of transduction following
incubation of prostate cells with BV for increasing lengths of time
one standard deviation. (C) Confocal microscopy images (single slice or Z-stack) of BV-transduced LNCaP, PC3 or PNT1A cells at 8 h post-transduction
(MOI = 500). Red fluorescence indicates BV capsid (anti-vp39), nuclear staining in blue (DAPI) and BV-driven EGFP expression in green.
doi:10.1371/journal.pone.0065557.g001
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revealed a difference in the rate of transgene expression between
highly susceptible malignant and poorly susceptible non-malignant
cell lines, suggesting that differences existed in the process of
cellular uptake and nuclear trafficking. However, in the non-
malignant cell line PNT1a, we observed viral capsids within the
cytoplasm and no obvious defect in the efficiency of nuclear
penetration. Further investigation into DNA release from the virus
capsid and transcriptional activation is required, since our related
research has shown that PNT1A and PNT2C2 cells are also
difficult to transfect with non-viral methods (unpublished data).
The primary patient-derived prostate epithelial cell cultures
used in this study represented a clinically relevant model for
Figure 2. BV transduction of primary prostate epithelial cells. (A) Percentage of EGFP-positive cells at 48 h post-transduction with Bv-[CMV-
EGFPCAT] at MOI = 500 for increasing lengths of time in three primary malignant prostate epithelial samples (Gleason 6, 7 or 8/9), maintained in a
basal state by culture in KSFMsup (&), or cultured in differentiating conditions in DH10 (m). Error bars depict 2/+ one standard deviation. (B)
Localisation of BV capsids in primary epithelial cells from a Gleason 8/9 tumour grown in a bilayer, either 1 h or 16 h after incubation with Bv-[CMV-
EGFPCAT] at MOI = 250. Red fluorescence indicates BV capsids detected with anti-vp39, nuclear DAPI staining is shown in blue and BV-driven EGFP
expression in green. Confocal images of the upper layer of cells (luminal-like; at an average z-distance of 14.58 mm from the ventral position) and
lower layer (basal-like; at an average z-distance of 6.47 mm from the ventral position) are shown. (C) Frequency (normalised to mock= 1%) or mean
fluorescence intensity of EGFP-positive primary stromal cells derived from malignant or benign biopsies 24 h following transduction with Bv-[CMV-
EGFPCAT] at MOI = 500.
doi:10.1371/journal.pone.0065557.g002
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assessing the BV vector [47]. These cultures, like the prostate
tumour itself, contained a heterogeneous mix of malignant and
non-malignant cells, represented in varying proportions between
patient samples. The range of Gleason score tumours we
employed demonstrated that BV was able to transduce multiple
stages of prostatic disease, yet Gleason score does not determine
differentiation status. BV demonstrated a preferential homing
ability for basal-like proliferating cells, rather than more differen-
tiated luminal-like cells. This difference in transduction was not
unexpected, since many vectors, including retrovirus and adeno-
associated virus, are less efficient at penetrating terminally-
differentiated cells [48,49], and even vectors capable of transduc-
ing quiescent cells perform better in proliferating cells [50]. Yet, as
tissue and tumour growth are driven by an undifferentiated basal
cell component, the enhanced ability of BV to target this cell
population is likely to be an advantage in achieving longer-term
tumour control. Our observation that a substantial proportion of
differentiated primary cells could be effectively transduced by BV
within four hours is also encouraging. BV is very stable in liquid
solution compared to many other viruses, which deteriorate
following prolonged incubation at room temperature or higher.
Therefore, the need for BV to persist for up to four hours in a
tumour environment is highly achievable. We also observed highly
efficient BV transduction of prostate stromal cells, a finding that
Figure 3. BV transduction of cells growing in three dimensions. (A) PC346C spheroids transduced with Bv-[CMV-EGFP] (or mock transduced)
at 3 days post-infection. (B) PC346C tumours harvested from xenografted mice at 3 days post-infection with BV at 36107 (one representative image
shown) or 16108 (two representative images shown) pfu per inoculation. Red fluorescence shows cell nuclei (Hoescht), while BV-driven EGFP
expression is shown in green. Arrows indicate the site of intratumoural BV injection.
doi:10.1371/journal.pone.0065557.g003
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has positive implications for the reduction of prostate tumour
burden, since stromal cells encourage tumour growth along the
invasion front [40]. Compared to epithelial cells, BV was able to
achieve a much higher rate of cellular transduction in a shorter
time in stromal cells, which may be related to increased levels of
HSPGs in stromal relative to epithelial compartments [51,52].
The ability of gene therapy vectors to penetrate through cell
layers is an important consideration in many clinical situations
involving solid tumours. Some vectors, such as the commonly used
type C adenovirus, are unable to penetrate the luminal cell barrier,
and only rarely diffuse more than one cell layer from an injection
needle track unless they are replication-competent [20]. The
spread of BV infection within a natural insect host emphasises its
ability to penetrate through different cell types [53,54]. We
demonstrated that BV was able to migrate through the tight outer
layer of in vitro malignant prostate spheroids into second and third
cell layers. As these spheroids were hollow, it was not possible to
more fully delineate the capacity for complete core penetration.
Perhaps most importantly, BV showed a good level of penetration
through xenograft tumours, even with a relatively low inoculum of
virus particles. With the recent establishment of techniques to
produce a highly concentrated clinical-grade BV preparation
suitable for human trials [55], an even more thorough coverage of
the tumour may be achievable, based on the difference between
the two BV doses we evaluated.
While we observed high BV transduction rates in both
malignant prostate epithelial and stromal cultures, the use of the
NTR/CB1954 GDEPT approach, which exhibits a strong
bystander effect, obviates the need for complete transduction
coverage [56]. A pronounced bystander effect has previously been
Figure 4. Reduction in cell viability following transduction with a BV expressing a nitroreductase-IRES-EGFP expression cassette
and treatment with the pro-drug CB1954. (A) Percentage of non-viable cells at 48 h post-transduction with BV-[CMV-NTR-EGFP] (MOI = 500) and
treatment with CB1954 in a panel of prostate cell lines, shown relative to frequency of transduced cells and adjusted for untreated controls.
Malignant cell lines: PC346C (¤), PC3 (m),LNCaP (&), P4E6 (6); Non-malignant cell lines: PNT1A (+), PNT2C2 (N). Statistics represent t-test between
PC346C/PC-3/LNCaP vs. PNT1A/PNT2C2. (B) Percentage of non-viable cells at 30 h post-transduction with BV-[CMV-NTR-EGFP] and treatment with
CB1954 in individual primary prostate epithelial cell samples (n = 3 malignant and n= 2 non-malignant), adjusted for untreated controls.
doi:10.1371/journal.pone.0065557.g004
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observed using this GDEPT approach after transduction of as few
as 10% of cells within a culture [57,58], and has been observed to
be even more effective in three-dimensional cultures [59] and
therefore tissues, where the permeable active metabolite is
transferred via intercellular junctions. Although we analysed the
outcomes of pro-drug administration relatively early (48 h for
immortalised cell lines or 30 h for non-immortalised primary
samples) to maintain cell viability in control wells, we nevertheless
observed that the BV-delivered NTR/CB1954 pro-drug system
efficiently killed a range of prostate cell types in direct proportion
to the frequency of positively transduced cells. In cell lines, there
was a differential in the extent of killing between malignant and
non-malignant samples, which was less evident in primary
samples. This could reflect a practical limitation of our in vitro
primary cell MTS assay conditions, where the earlier analysis
(30 h) of killing necessary to ensure high cell viability in control
wells may have attenuated the ability of the BV/NTR/CB1954
GDEPT to achieve maximum effectiveness.
Although this research provides strong evidence demonstrating
the feasibility of BV as a gene therapy vector for prostate cancer, it
also highlights further areas that must continue to be explored.
While administration of BV intratumourally in xenograft models
was successful, further studies of the ability of BV to migrate to and
infect distal metastases are still required. The extension of the BV-
driven GDEPT approach to in vivo models of prostate cancer is of
great clinical significance, and is currently being explored and
developed. Further, the application of the BV-[CMV-NTR-
EGFP] transduction/pro-drug conversion system as a low toxicity
means to presensitise prostate tumours to the effects of radiation,
an approach referred to by Hanna et al [60], could be a
complementary clinical approach. Nonetheless, the findings
presented here support the use of BV as a rational gene therapy
vector for human prostate cancer. BV does not suffer from the
common restrictions of other viral gene therapy vectors, such as
limited DNA capacity and pre-existing virus-specific immune
responses, and can easily be modified to incorporate other
desirable features, such as targeting and immune shielding. BV
displays multiple attributes that recommend its application in a
gene therapeutic approach for prostate cancer, and with
appropriate regulatory permission, BV has great potential for
achieving clinical success.
Supporting Information
Figure S1 Induction of differentiation through changes
in growth conditions in primary prostate epithelial cell
cultures. Malignant epithelial cells derived from a primary
prostate biopsy of Gleason score 8/9 were cultured in either
KSFMsup or DH10 medium. (A) Morphological differences
between cells cultured in KSFMsup or DH10 medium, analysed
by phase contrast microscopy. (B) Dual immunocytochemistry
performed on an alternate batch of the same cells cultured in
KSFMsup or DH10 medium. Basal anti-cytokeratins 1, 5, 10 and
14 were conjugated to Alexa 568 (red fluorescence), while luminal
anti-cytokeratin 18 was conjugated to FITC (green fluorescence).
Cells were counterstained with DAPI to enable nuclear visualisa-
tion (blue fluorescence). Co-localisation of basal and luminal
fluorescence is shown in yellow (arrow). All images taken at x20
magnification.
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